Austrian Registry for Adults with Chronic Lymphocytic Leukemia Tracking Long-Term Outcomes and Treatments

What this Trial Is About

Researchers are observing patients with Chronic Lymphocytic Leukemia CLL to better understand this disease which has long been considered incurable except in rare cases involving stem cell transplants. Recent advances like chemoimmunotherapy and new drugs targeting specific disease mechanisms have improved outcomes for some patients, but long-term effects and safety of new treatments remain uncertain. This Austrian registry study aims to systematically collect data on CLL patients across the country to fill this knowledge gap. This study collects information by reviewing existing medical records from multiple centers without altering any treatment plans. It gathers data on patient characteristics, genetic profiles, treatments received, side effects, and disease progression over time. The registry relies solely on routine clinical data already recorded in patient charts, ensuring no extra tests or procedures are required for participation. Participants will be followed longitudinally through their medical records until death or loss to follow-up. Data such as survival, tumor progression, treatment patterns, coexisting conditions, and toxicities are monitored for up to seven years. Personal identifiers are replaced with unique codes to protect confidentiality. The study does not interfere with standard care and requires written consent before data entry from living patients only, with no consent needed for deceased individuals.

AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry